In Brief
Mst1 and Mst2 are protein kinases that activate the hippo tumor suppressor pathway, yet their mode of regulation is poorly understood. Rawat et al. show that H-ras V12 induces Mst1/Mst1 and Mst2/ Mst2 homodimers to switch partners to form Mst1/Mst2 heterodimers. These heterodimers are inactive, promoting YAP activation and oncogenic transformation.
SUMMARY
The protein kinases Mst1 and Mst2 have tumor suppressor activity, but their mode of regulation is not well established. Mst1 and Mst2 are broadly expressed and may have certain overlapping functions in mammals, as deletions of both Mst1 and Mst2 together are required for tumorigenesis in mouse models [1] [2] [3] . These kinases act via a three-component signaling cascade comprising Mst1 and Mst2, the protein kinases Lats1 and Lats2, and the transcriptional coactivators Yap and Taz [4] [5] [6] . Mst1 and Mst2 contain C-terminal SARAH domains that mediate their homodimerization as well as heterodimerization with other SARAH domain-containing proteins, which may regulate Mst1/Mst2 activity. Here we show that, in addition to forming homodimers, Mst1 and Mst2 heterodimerize in cells, this interaction is mediated by their SARAH domains and is favored over homodimers, and these heterodimers have much-reduced protein kinase activity compared to Mst1 or Mst2 homodimers. Mst1/Mst2 heterodimerization is strongly promoted by oncogenic H-ras, and this effect requires activation of the Erk pathway. Cells lacking Mst1, in which Mst1/ Mst2 heterodimers are not possible, are resistant to H-ras-mediated transformation and maintain active hippo pathway signaling compared to wild-type cells or cells lacking both Mst1 and Mst2. Our results suggest that H-ras, via an Erk-dependent mechanism, downregulates Mst1/Mst2 activity by inducing the formation of inactive Mst1/Mst2 heterodimers.
RESULTS AND DISCUSSION

Mst1 and Mst2 Heterodimerize in Cells
In a co-immunoprecipitation screen for Mst1 interactors [7] , we found an abundance of Mst2-derived peptides (Table S1 ). As Mst1/Mst2 heterodimers have not been reported previously, this finding prompted us to determine if Mst1 and Mst2 formed a complex in cells. HEK293 cells were transfected either with expression vectors for Myc-tagged Mst1 alone or with Myc-tagged Mst1 and HA-tagged Mst2 together, and co-immunoprecipitations were performed. We found that HA immunoprecipitates contained Myc-tagged Mst1 ( Figure 1A ). Similar to the results using exogenous Mst1 and Mst2, we found that HA-SBPtagged Mst2 co-precipitated endogenous Mst1 ( Figure 1B ). Antibodies against murine Mst1 and Mst2 do not cross-react and thus can be used to distinguish Mst1 from Mst2 ( Figure 1C ). We used these antibodies to perform proximity ligation assay (PLA) in HEK293 cells (Supplemental Experimental Procedures). Our results suggested that endogenous Mst1 and Mst2 form heterodimers in cells ( Figures 1D and 1F) . To test the specificity of the assay, we repeated the PLA using Mst1
Mst2
+/+ and Mst1
f/À mouse embryonic fibroblasts (MEFs). We found heterodimer formation only in Mst1
, suggesting that there is not significant crossreactivity between the secondary antibodies and consistent with the idea that Mst1 and Mst2 can heterodimerize in cells expressing both Mst isoforms ( Figures 1E and 1F ). To further confirm heterodimer formation, we generated a tetracyclineinducible HA-SBP-Mst2-expressing stable cell line (Mst2-FlpIn 293). We induced Mst2-Flp-In 293 cells with tetracycline to express SBP-Mst2 at approximately endogenous levels [7] , and then we used streptavidin beads to pull down SBP-Mst2 and probed the protein complex with anti-Mst1 antibodies. Detection of endogenous Mst1 in the protein complex further confirmed heterodimer formation ( Figure 1G ).
As both the kinase and SARAH domains might contribute to the homodimerization of Mst1 and Mst2 proteins [8] , we asked what domains mediate the heterodimerization of Mst1 and Mst2. We constructed the following four forms of Myc-Mst1: full-length (1-487), Mst1 lacking the SARAH domain (1-430), Mst1 kinase domain only , and Mst1 minus the kinase domain (276-487) (Figure 2A ). We tested each form for binding to full-length HA-Mst2. We found that full-length Mst1 as well as Mst1 comprising only the autoinhibitory domain plus the SARAH domain (276-487) were able to bind Mst2, whereas Mst1 kinase domain only and Mst1 lacking the SARAH domain (1-430) were not able to bind Mst2 ( Figure 2B ). These results indicate that the SARAH domain is required for Mst1/Mst2 heterodimerization. To further characterize this interaction, we also tested if kinase activity and T-loop phosphorylation of Mst1 or Mst2 play a role in heterodimerization. We co-transfected HEK293 cells with HA-Mst1 along with wild-type (WT) MycMst2 or Myc-Mst2 K56R (KR), a kinase-dead form of Mst2, or Myc-Mst2 T180D (TD), an activation loop mutant of Mst2. Co-immunoprecipitation experiments revealed that both the kinase-dead form and the activation loop mutant of Mst2 were able to bind Mst1, suggesting that kinase activity and T-loop phosphorylation of Mst2 are not required for heterodimeric binding to Mst1 ( Figure S1A ). As with Mst2, mutation of the Mst1 catalytic Lys residue (K59R) or substitution at its T-loop phosphorylation site (T183A) also did not affect heterodimerization ( Figure S1B ). These experiments suggest that kinase activity is not required for heterodimer formation between Mst1 and Mst2.
To assess the relative levels of homodimers versus heterodimers, we transfected HEK293 cells with expression vectors encoding full-length HA or Myc-tagged Mst1 and Mst2, as indicated ( Figure 2C ). Mst1 and Mst2 were expressed at nearly equal levels. Under these conditions, co-immunoprecipitation revealed a substantial level ($60%) of Mst1/Mst2 heterodimers relative to Mst1/1 and Mst2/2 homodimers ( Figures 2C  and 2D ).
The relatively high levels of Mst1/Mst2 heterodimers suggested a strong affinity of these proteins for each other. We therefore determined the dissociation constants for homo-and heterodimers of the Mst1 and Mst2 SARAH domains using a fluorescence resonance energy transfer (FRET)-based approach. Variants of the Mst1, Mst2, and Mst2-LW SARAH domains containing a C-terminal Cys were expressed in bacteria and purified (see the Supplemental Experimental Procedures). Modification with the thiol-reactive IAEDANS (Supplemental Experimental Procedures) yielded the AEDANS-labeled derivatives Mst1-AED, Mst2-AED, and Mst2-LW-AED. Since SARAH domains associate in an antiparallel orientation [9, 10] , a unique Trp residue at the N-terminal end of the Mst1 SARAH domain can be used as a FRET donor, while the AEDANS label at the C terminus of the adjacent subunit in the dimer serves as an acceptor (inset, See also Figure S1 . Figure 2F ). For Mst2, an equivalent Trp residue was introduced by site-directed mutagenesis (Mst2-LW).
On the basis of nuclear magnetic resonance (NMR) and crystal structures of SARAH domain homodimers [11] , we estimated a distance of 12 Å for the inter-subunit donor-acceptor pair, whereas the distance between the Trp donor and the acceptor on opposite ends of the helical monomer was $57 Å . Thus, we expected efficient energy transfer for the inter-subunit Trp-AEDANS pair (Fö rster distance R 0 $18 Å ) and a negligible contribution from intra-subunit FRET. To confirm this, we recorded fluorescence spectra for the Mst1 ( Figure S2 ) and Mst2 SARAH domains under native and denaturing (9 M-urea) conditions. Upon excitation of the Trp, we observed a partially quenched donor (Trp) emission band compared to an unlabeled sample and a pronounced acceptor (AEDANS) emission band for each of the homodimers. For Mst1, we estimated a donor-acceptor distance, R DA , of 15 Å , which closely matches that observed in the NMR structure [9] . In the presence of 9 M urea, which results in unfolded monomers, donor quenching and acceptor enhancement were less pronounced, consistent with an increase in average donor-acceptor distance for the unfolded monomer (R DA $16 Å ). To determine the dissociation constant, K D , for the Mst1 homodimer, we recorded fluorescence spectra at protein concentrations from 40 down to 0.6 mM ( Figure 2E 
In Figure 2G , we compare the fluorescence spectra for equimolar (3-mM) solutions of unlabeled Mst1 (which has a Trp near the N terminus, Trp439), Mst2-AED (which has no tryptophan, but a C-terminal AEDANS label), and a 1:1 mixture of the two SARAH domains. In the mixed sample, the donor band is $2-fold lower than that of Mst1 while the acceptor band is strongly enhanced compared to Mst2-AED, which is consistent with efficient FRET from Trp439 in Mst1 to the AEDANS at the C terminus of Mst2-AED. After accounting for labeling efficiency (18%), we calculated a FRET efficiency of 0.91, which corresponds to a donor-acceptor distance of 12.1 Å , similar to that obtained for the Mst1 homodimer. These results provide unambiguous evidence for the formation of an antiparallel heterodimer (inset, Figure 2G ). To determine the K D value for the Mst1/Mst2 heterodimer, unlabeled Mst1 SARAH domain was titrated against Mst2-AED (1 mM), and the observed increase in acceptor fluorescence was plotted versus Mst1 concentration ( Figure 2H ). The K D obtained by least-squares fitting of a 1:1 binding model was 0.72 ± 0.03 mM. This value is substantially lower than that of the corresponding homodimers (6.5 and 4.3 mM, respectively), indicating that heterodimer formation is favored over self-association of either SARAH domain.
Mst1/Mst2 Heterodimers Have Impaired Kinase Activity
Having confirmed heterodimer formation between Mst1 and Mst2, we tested the effect of heterodimer formation on kinase activity. To compare the activities of homo-and heterodimers, we isolated Mst1/Mst2 heterodimers and corresponding Mst1/ Mst1 and Mst2/Mst2 homodimers using a sequential immunoprecipitation strategy ( Figure 3A ). Mst1/Mst2 double knockout (KO) HEK293 cells [13] were co-transfected with HA-SBP-Mst1 and Myc-Mst2. To isolate Mst1/Mst2 heterodimers, HA-SBPMst1 was immunoprecipitated using streptavidin beads and complexes were eluted from the beads with 2 mM biotin. This eluate was then immunoprecipitated with anti-Myc-agarose beads to isolate HA-SBP-Mst1/Myc-Mst2 heterodimers. MycMst2 homodimers and monomers were isolated by immunoprecipitating HA-SBP-Mst1-depleted lysates with anti-Mycagarose beads. Similarly, HA-SBP-Mst1 homodimers were immunoprecipitated with streptavidin beads from Myc-Mst2-depleted lysates. Mst1/Mst1 and Mst2/Mst2 homodimers and Mst1/Mst2 heterodimers were adjusted to similar levels and assessed for purity using SDS-PAGE ( Figure 3B ). To measure the kinase activities of each of the three species, we took equal amounts of each species and performed in vitro kinase assays using MBP or Mob as a substrate. The kinase activity of Mst1/ Mst2 heterodimers was much lower compared to that of Mst1/ Mst1 or Mst2/Mst2 homodimers, as shown by p-MBP and p-Mst levels ( Figure 3C; Figure S3A ) or p-Mob levels, a highly specific Mst1/Mst2 substrate ( Figure 3D) . Interestingly, Mst2 homodimers showed more robust activation compared to Mst1 homodimers ( Figure 3E ). To confirm that the signals in phosphoblots reflect protein kinase activity, we also performed these experiments in the absence of ATP, which resulted in loss of the signals ( Figure 3F ). Mutants of Mst1 and Mst2 that could not dimerize due to excision of the C-terminal SARAH domain failed to exhibit cross-inhibition when incubated together ( Figure S3B ).
To determine if the suppressive effect of heterodimerization on enzyme activity required the kinase activities of Mst1 and/or Mst2, we performed kinase assays using Mst1/Mst2 homodimers or heterodimers in which one or both partners were inactive. As expected, homodimers of kinase-dead Mst2 and heterodimers of kinase-dead Mst2 with WT Mst1 displayed lower activity compared to their WT counterparts ( Figure 3G) . Interestingly, homodimers of T-loop mutants of Mst2 and heterodimers of T-loop mutants of Mst2 with WT Mst1 showed activity similar to their WT counterparts ( Figure 3G ). Similar results were obtained when kinase-dead and T-loop mutants of Mst1 were tested (data not shown). These results suggest that T-loop phosphorylation is uncoupled from enzyme activity in the Mst1/Mst2 heterodimers.
Mst1/Mst2 Heterodimerization Is Promoted by H-ras in an Erk-Dependent Manner
To determine how Mst1/Mst2 heterodimerization is regulated, we asked if oncogenic stimuli alter the levels of Mst1/Mst2 heterodimers. Cells were co-transfected with expression vectors for activated H-ras, c-Raf, Nore1, or Akt1 ( Figure S4A ) and assessed for Mst1/Mst2 heterodimerization using PLA. As shown in Figures 4A and 4B , expression of activated H-ras markedly increased the amount of Mst1/Mst2 heterodimers. c-Raf had a more modest positive effect, whereas Nore1 and Akt only slightly increased heterodimerization. Interestingly, the effect of H-ras on inducing Mst1/Mst2 heterodimers was blocked completely by the addition of a Mek inhibitor ( Figure 4C ), which suggests that a Ras-Mek-Erk pathway regulates Mst1/Mst2 heterodimerization. We also tested if H-ras-induced Mst1/Mst2 heterodimer formation is accompanied by a loss of hippo signaling. Western blot analysis confirmed that cells expressing H-ras had lower Mst1/Mst2 activity and decreased downstream signaling, as p-Mst1/Mst2, pLats, pMob1, and pYap levels were lower in H-ras-transfected cells compared to non-transfected cells (Figure 4G ; Figure S4B ). As with its effect on Mst1/Mst2 heterodimerization, treatment with a Mek inhibitor blocked the effect of H-ras on Mst1/Mst2 activity and hippo pathway signaling ( Figure S4B ).
Cells Lacking Mst1 Resist Transformation by Activated H-ras
If Mst1/Mst2 heterodimerization reflects an important means for downregulating the tumor-suppressive activity of the hippo pathway, then cells lacking one of the Mst partners should be unable to limit Mst1/Mst2 activity and, therefore, despite losing a putative tumor suppressor protein, be harder to transform than WT cells. To test this seemingly paradoxical idea, we transfected WT (Mst1 +/+ Mst2 +/+ ), heterozygous (Mst1 À/À Mst2 f/À ), and
) MEFs with activated H-ras, and we performed three assays-cell proliferation, soft agar colony formation, and focus formation-to compare the transforming ability of this oncoprotein in these cells. As expected, transfection of WT MEFs with H-ras promoted increased focus formation, anchorage-independent growth, and proliferation ( Figures 4D-4F and 4H) . Interestingly, H-ras lacked this effect in heterozygous Mst1 These results are consistent with the idea that H-ras-induced Mst1/Mst2 heterodimer formation in WT cells inhibits the tumor suppressor function of the hippo pathway, and that this activity is lost in cells lacking Mst1 or Mst2 or both Mst1 and Mst2. These results also are consistent with those of Romano et al., who reported that H-ras inactivates Mst1 and Mst2 in HeLa cells [15] . Signaling analysis was consistent with the growth and transformation effects: in Mst1
Mst2
f/À MEFs only, H-ras failed to inactivate Mst2 signaling, as evidenced by elevated p-Mst1/Mst2, p-Lats, p-Mob, p-Yap, and cleaved caspase-3 ( Figure 4G ). Exogenous expression of Mst1 in Mst1 À/À Mst2 f/À MEFs reversed the H-rasinduced signaling profile, i.e., these cells displayed low levels of p-Mst1/Mst2, p-Lats, p-Mob, p-Yap, and cleaved caspase-3 and proliferated faster ( Figures 4G and 4H) . Similarly, exogenous expression of Mst1 in Mst1
À/À MEFs converted the H-ras-induced signaling profile to a growth-inhibited state characterized by elevated hippo pathway activity (Figures 4G and 4H) . (B) Mst1/Mst2 double KO HEK293 cells [13] were transfected with Mst1 and Mst2. Homodimers and heterodimers were isolated as described in the Supplemental Experimental Procedures, and they were adjusted to similar levels and separated by SDS-PAGE, followed by Coomassie blue staining. (C and D) Homodimers and heterodimers were subjected to in vitro kinase assay using (C) MBP as a substrate in the presence of [g-32 P]ATP, or they were subjected to in vitro kinase assay using (D) Mob1 as a substrate, with subsequent western blot analysis using anti-phospho Mob1 antibodies. (E) Mst1/Mst2 homodimers and heterodimers were subjected to in vitro kinase assay for the indicated time points using Mob1 as a substrate.
(F) Mst1/Mst2 homodimers and heterodimers were subjected to in vitro kinase assay using Mob1 as a substrate in the absence and presence of ATP.
(G) HEK293 cells were co-transfected with WT-HA-Mst1 along with WT-Myc-Mst2, Myc-Mst2 K59R, or Myc-Mst2 T183D. Corresponding Mst1/Mst2 homodimers and heterodimers were isolated and subjected to in vitro kinase assay using Mob1 as a substrate. See also Figure S3 .
The role of Mst1/Mst2 homodimerization in activation is controversial. Some studies suggest that Mst1/Mst2 homodimerization is required for autophosphorylation and activation of these kinases [8, 16, 17] , while others indicate that homodimer formation is not required for its activity [8, 18] . In addition to forming homodimers, Mst1 and Mst2 have been shown to heterodimerize with other SARAH domain-containing proteins, such as the RASSF family of proteins [8, [19] [20] [21] . Interaction with RASSF proteins has been shown both to positively and negatively regulate Mst1/ Mst2 activity; however, an association of Mst1 to Mst2 to form Mst1/Mst2 heterodimers has not been reported previously.
There are relatively few cytosolic protein kinases known to form stable heterodimers. Perhaps the best understood heterodimerization event is provided by the B-Raf and c-Raf proteins, which dimerize in response to mitogenic stimuli or upon exposure to B-Raf inhibitors [22] [23] [24] . Unlike the Mst1/Mst2 heterodimer reported here, B-Raf/c-Raf heterodimers have higher protein kinase activity than the corresponding homodimers [25] . Interestingly, another set of STE20 family kinases, p21-activated kinase (Pak)1 and Pak3, also have been shown to heterodimerize. Like the Mst1/Mst2 pair, Pak1/Pak3 heterodimers also show low kinase activity [26] .
It was shown recently that Mst1 homodimers in cardiac tissue are disrupted via TORC2-catalyzed phosphorylation at S438 within the Mst1 SARAH domain [17] . While the effects of TORC2 on Mst2 homodimerization and Mst1/Mst2 heterodimerization were not studied in this work, it is interesting to note that the Mst2 SARAH domain lacks the equivalent serine residue found in Mst1. It also has been reported that Rassf5 binding to Mst2 disrupts Mst2 homodimers and inhibits their ability to become activated [8] . In this setting, displacement of one of the two Mst2 proteins in the dimer by Rassf5 is expected to prevent trans-autophosphorylation of the activation loop. The mechanism underlying loss of activity in Mst1/Mst2 heterodimers is presumably based on different structural grounds, as two kinase domains would still be present, as in homodimers. It is possible that the heterodimer adopts a geometry that prevents productive interactions required for trans-autophosphorylation of the kinase domains. This mechanism is analogous to that reported for Raf/Mst heterodimers, where binding of c-Raf or B-Raf to a C-terminal domain of Mst2 or Mst1, respectively, results in Mst1/Mst2 inhibition [27, 28] . Conversely, Abl-mediated phosphorylation of Mst2 at Y81 disrupts the c-Raf/Mst2 heterodimer and enhances Mst2 homodimerization and activity [29] . Both K-ras and H-ras previously have been shown to regulate the Hippo-Yap pathway. For example, mutant K-ras has been shown to positively regulate Mst2 activity via binding to Rassf1A, which in turn binds and activates Mst2 [15, 30] . Also, it has been reported that withdrawal of K-ras G12D expression in murine pancreatic ductal adenocarcinoma (PDAC) tumors in time leads to Yap1 gene amplification and overexpression, enabling tumor growth and maintenance, suggesting that Yap1 can substitute for oncogenic K-ras in PDAC and other malignancies [31, 32] . Unlike K-ras, H-ras-Erk signaling previously has been shown to impede the Hippo pathway via phosphorylation of the Ajuba homolog WTIP, which then binds to the LATS/WW45 complex and thereby inhibits phosphorylation of Yap [33] . Our results suggest a second mechanism for Erk-mediated inhibition of the Hippo pathway through the formation of low-activity Mst1/Mst2 heterodimers. Presumably, this latter mechanism would be inoperative in cells lacking either Mst1 or Mst2 due to mutational loss of epigenetic silencing, as suggested by our studies of H-ras transformation in Mst1-null MEFs (Figures 4D and 4E ). 
